Delivery Order SPE2DB22D1017-SPE2DB25FG4ME
- Not listed
- The Defense Logistics Agency awarded a $72,034 delivery order to AmerisourceBergen Drug Corp on July 3, 2025, for the supply of Xolair 150 mg/mL syringes, with completion scheduled for July 25, 2025. This firm fixed-price, non-set-aside contract is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xolair 150 mg/ml syringes, with a contract ceiling value of $5,402.58 and an ultimate completion date of August 19, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xolair 75 mg/0.5 ml syringes with a ceiling value of $1,080.54 and a firm fixed price structure. This delivery order is non-set-aside and represents a competitively awarded contract with an ultimate completion date of August 11, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for Xolair 150 mg/ml syringes valued at $2,881.36, with completion scheduled for September 4, 2025. This firm fixed-price, competitively awarded delivery order represents a non-set-aside procurement executed through the company's existing Indefinite Delivery Contract with the Defense Logistics Agency Troop Support Medical (SPE2DX). AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of XOLAIR 150 mg/ml syringes, with a contract ceiling value of $5,762.72 and an ultimate completion date of August 19, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation, performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Xolair 150 mg/mL syringes, valued at $17,288.16. This firm fixed-price contract, with an ultimate completion date of August 14, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $14,406.80 to AmerisourceBergen Drug Corp for the supply of Xolair 150 mg/ml syringes. The contract, issued on June 24, 2025, with an ultimate completion date of July 16, 2025, was awarded on a non-competitive, firm fixed-price basis. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Xolair 150 mg/mL syringes, valued at $10,805.10. This is a firm fixed-price delivery order with a completion date of August 20, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's proven capability to meet federal pharmaceutical procurement...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on June 2, 2025, for the supply of Xolair 150 mg/ml syringes, with a firm fixed price ceiling value of $6,483.06 and an ultimate completion date of June 24, 2025. This non-set-aside, competitively awarded contract represents a single delivery order under the company's larger pharmaceutical supply framework with the federal government. The place of performance is listed as AmerisourceBergen's...
- The Defense Logistics Agency awarded a $10,805.10 delivery order to AmerisourceBergen Drug Corp for Xolair 150 mg/ml syringes, with an ultimate completion date of September 9, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be performed at the vendor's Corporate...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG4MEDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 7, 2025, for the supply of Xolair 150 mg/ml syringes with a ceiling value of $4,322.04. This is a firm fixed price delivery order with an ultimate completion date of June 30, 2025, and was competitively awarded with no set-aside designation. The order is issued under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical, which is valued at $999,999,999 and extends through December 2026. This parent contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is a critical vendor for federal medical procurement and serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company demonstrates significant capability in fulfilling federal medical supply requirements across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, vaccines, and medical devices. This delivery order for Xolair, a biologic medication commonly used for asthma and chronic urticaria treatment, reflects the company's ongoing role in supporting military and federal healthcare operations through its extensive pharmaceutical logistics network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 6/7/25 |